NIKKEI 225
38,837.46 -85.54 (-0.22%) HANG SENG
18,444.11 +41.11 (+0.22%) CRUDE OIL
73.20 -1.02 (-1.37%) GOLD FUTURES
2,346.50 -22.80 (-0.96%) DOW
38,711.29 +140.26 (+0.36%) Bitcoin GBP
55,066.23 +784.10 (+1.44%)
AZN Oct 2024 75.000 call
- PR Newswire
AbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored autologous GPC3 CAR-T, in patients with advanced hepatocellular carcinoma, at ASCO Annual Meeting 2024
AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced preliminary safety and efficacy results from its first time in human investigator-initiated trial (IIT) of C-CAR031 in connection with the Company's oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation shared data indicati
- Zacks
Astrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know
In the latest trading session, Astrazeneca (AZN) closed at $78.99, marking a +1.24% move from the previous day.
- Business Wire
TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial
WILMINGTON, Del., June 02, 2024--Positive results from the LAURA Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) for patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) whose tumors have exon 19 deletions or exon 21 (L858R) mutations, after chemoradiotherapy (CRT) compared to placebo after CRT.
